Holen Sie sich die Stockscreener-App
20.90
0.52%
-0.11
Handel nachbörslich:
21.31
0.41
+1.96%
Schlusskurs vom Vortag:
$21.01
Offen:
$21.01
24-Stunden-Volumen:
1.31M
Relative Volume:
1.09
Marktkapitalisierung:
$2.55B
Einnahmen:
$460.48M
Nettoeinkommen (Verlust:
$142.80M
KGV:
17.71
EPS:
1.18
Netto-Cashflow:
$221.79M
1W Leistung:
-0.24%
1M Leistung:
-7.03%
6M Leistung:
-8.61%
1J Leistung:
+22.94%
1-Tages-Spanne:
$20.76
$21.30
1-Wochen-Bereich:
$20.71
$21.70
52-Wochen-Spanne:
$15.34
$26.58
Catalyst Pharmaceuticals Inc Stock (CPRX) Company Profile
Firmenname
Catalyst Pharmaceuticals Inc
Sektor
Branche
Telefon
(305) 529-2522
Adresse
355 ALHAMBRA CIRCLE, CORAL GABLES
Vergleichen Sie CPRX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CPRX
Catalyst Pharmaceuticals Inc
|
20.90 | 2.56B | 460.48M | 142.80M | 221.79M | 1.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Catalyst Pharmaceuticals Inc Stock (CPRX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-04 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-11-18 | Eingeleitet | Stephens | Overweight |
| 2024-03-14 | Eingeleitet | Citigroup | Buy |
| 2024-03-07 | Eingeleitet | BofA Securities | Buy |
| 2023-12-21 | Eingeleitet | Oppenheimer | Outperform |
| 2022-08-24 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Fortgesetzt | Piper Jaffray | Overweight |
| 2016-10-05 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2016-04-26 | Herabstufung | Piper Jaffray | Overweight → Neutral |
| 2014-09-30 | Bestätigt | ROTH Capital | Buy |
| 2014-09-16 | Bestätigt | ROTH Capital | Buy |
| 2014-09-15 | Bestätigt | H.C. Wainwright | Buy |
| 2013-10-21 | Bestätigt | Aegis Capital | Buy |
| 2013-09-24 | Eingeleitet | Maxim Group | Buy |
| 2013-09-06 | Bestätigt | Aegis Capital | Buy |
| 2013-04-18 | Eingeleitet | Aegis Capital | Buy |
| 2012-08-27 | Hochstufung | Rodman & Renshaw | Mkt Perform → Mkt Outperform |
| 2009-10-01 | Hochstufung | Merriman | Sell → Neutral |
| 2009-05-29 | Herabstufung | Hapoalim | Neutral → Underperform |
| 2009-05-29 | Herabstufung | Merriman Curhan Ford | Buy → Sell |
| 2008-12-15 | Eingeleitet | Merriman Curhan Ford | Buy |
| 2007-11-28 | Eingeleitet | Rodman & Renshaw | Mkt Outperform |
| 2007-01-31 | Eingeleitet | Stifel Nicolaus | Buy |
| 2007-01-05 | Eingeleitet | First Albany | Buy |
Alle ansehen
Catalyst Pharmaceuticals Inc Aktie (CPRX) Neueste Nachrichten
What drives Catalyst Pharmaceuticals Inc. stock pricePhenomenal returns - jammulinksnews.com
Is Catalyst Pharmaceuticals Inc. a good long term investmentConsistently exceptional gains - printweek.in
Catalyst Pharmaceuticals Scheduled to Release Q2 2025 Financial Results on August 6, 2025 - Quiver Quantitative
Catalyst Pharmaceuticals to Report Second Quarter 2025 Financial Results on August 6, 2025 - GlobeNewswire
What analysts say about Catalyst Pharmaceuticals Inc. stockDynamic profit opportunities - jammulinksnews.com
Catalyst Pharmaceuticals Inc. Stock Analysis and ForecastPhenomenal wealth increase - Autocar Professional
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Value Stock - Yahoo Finance
Why Catalyst Pharmaceuticals Inc. stock is on top investor watchlistsSafe and Smart Investment Picks - Newser
Published on: 2025-07-17 22:44:23 - Newser
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics - Yahoo
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics - The Globe and Mail
Should Value Investors Buy Catalyst Pharmaceuticals (CPRX) Stock? - Yahoo Finance
Teacher Retirement System of Texas Sells 2,766 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
What makes Catalyst Pharmaceuticals Inc. stock price move sharplyFree Stock Tips Group - beatles.ru
Why Catalyst Pharmaceuticals Inc. stock attracts strong analyst attentionPro Trader Stock Focus - Newser
How Catalyst Pharmaceuticals Inc. stock performs during market volatilityRisk Aware High Growth Picks - Newser
Principal Financial Group Inc. Purchases 17,018 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Amalgamated Bank Decreases Stake in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Cambridge Investment Research Advisors Inc. Takes Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
GAMMA Investing LLC Acquires 579 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Institutional investors in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) lost 3.5% last week but have reaped the benefits of longer-term growth - simplywall.st
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Shares Sold by New York State Teachers Retirement System - Defense World
Why Catalyst Pharmaceutical (CPRX) is a Top Growth Stock for the Long-Term - Yahoo Finance
Allspring Global Investments Holdings LLC Sells 244,148 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - Defense World
Why Catalyst Pharmaceutical (CPRX) is a Top Value Stock for the Long-Term - Yahoo Finance
Catalyst Pharmaceuticals is Now Oversold (CPRX) - Nasdaq
Healthcare Stocks to Watch: Catalyst Pharmaceuticals, AVITA Medical, and Moleculin Biotech. - AInvest
Here's Why Catalyst Pharmaceutical (CPRX) is a Strong Growth Stock - Nasdaq
Catalyst Pharmaceuticals (NasdaqCM:CPRX) Reports Strong Q1 2025 Earnings Growth - Yahoo Finance
Stanley Laman Group Ltd. Acquires New Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
GAMMA Investing LLC Has $1.64 Million Position in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) - MarketBeat
Catalyst Pharmaceuticals (NASDAQ:CPRX) Trading Down 5.2% Following Insider Selling - MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Insider Sells $42,272.00 in Stock - MarketBeat
Trading (CPRX) With Integrated Risk Controls - news.stocktradersdaily.com
Preethi Sundaram Implements A Sell Strategy: Offloads $103K In Catalyst Pharmaceuticals Stock - Nasdaq
Insider Sell: Preethi Sundaram Sells Shares of Catalyst Pharmaceuticals Inc (CPRX) - GuruFocus
Preethi Sundaram Sells 2,324 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Stock - MarketBeat
117,374 Shares in Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Bought by Bridge City Capital LLC - MarketBeat
Director Of Catalyst Pharmaceuticals Sold $5.22M In Stock - Nasdaq
Strong Inflows Make Catalyst Stock an Outlier - FXEmpire
Insider Sell: Patrick Mcenany Sells 200,000 Shares of Catalyst P - GuruFocus
Finanzdaten der Catalyst Pharmaceuticals Inc-Aktie (CPRX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):